8-K
InMed Pharmaceuticals Inc. (INM)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported): September 25, 2023
INMED PHARMACEUTICALS INC.
(ExactName of Company as Specified in Charter)
| British Columbia | 001-39685 | 98-1428279 |
|---|---|---|
| (State or Other Jurisdiction<br><br> <br>of Incorporation) | (Commission File Number) | (IRS Employer<br><br> <br>Identification No.) |
| InMed Pharmaceuticals Inc.<br><br> <br>Suite 310 - 815 W. Hastings Street,<br><br> <br>Vancouver, B.C.<br><br> <br>Canada | V6C 1B4 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Company’s
telephone number, including area code: (604) 669-7207
Not
applicable
(FormerName or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Shares, no par value | INM | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item8.01 Other Events
On September 25, 2023, InMed Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2023 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.
The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
| Exhibit No. | Description |
|---|---|
| 99.1 | SEDAR filing submitted September 25, 2023 |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMED PHARMACEUTICALS<br> INC. | ||
|---|---|---|
| Date: September 25, 2023 | By: | /s/<br> Eric A. Adams |
| Eric<br> A. Adams<br><br> <br>President<br> and CEO |
2
Exhibit 99.1
| September 25, 2023 |
|---|
Filed via SEDAR
To All Applicable Exchanges and Securities Administrators
| Subject: | InMed Pharmaceutical Inc. (the "Issuer") |
|---|---|
| Notice of Meeting and Record Date |
Dear Sir/Madam:
We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders:
| Meeting Type: | Annual General Meeting |
|---|---|
| Meeting Date: | December 19, 2023 |
| Record Date for Notice of Meeting: | October 20, 2023 |
| Record Date for Voting (if applicable): | October 20, 2023 |
| Beneficial Ownership Determination Date: | October 20, 2023 |
| Class of Securities Entitled to Vote: | Common Shares |
| ISIN: | CA4576376012 |
| Issuer sending proxy materials directly to NOBOs: | No |
| Issuer paying for delivery to OBOs: | No |
| Notice and Access for Beneficial Holders: | Yes |
| Notice and Access for Registered Holders: | Yes |
In accordance with applicable securities regulations we are filing this information with you in our capacity as agent of the Issuer.
Yours truly,
Odyssey Trust Company
as agent for InMed Pharmaceutical Inc.